AU2002217266A1 - Antitumoral carbazoles - Google Patents

Antitumoral carbazoles

Info

Publication number
AU2002217266A1
AU2002217266A1 AU2002217266A AU1726602A AU2002217266A1 AU 2002217266 A1 AU2002217266 A1 AU 2002217266A1 AU 2002217266 A AU2002217266 A AU 2002217266A AU 1726602 A AU1726602 A AU 1726602A AU 2002217266 A1 AU2002217266 A1 AU 2002217266A1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
compound according
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217266A
Other languages
English (en)
Inventor
John Wilson Blunt
Dolores Garcia Gravalos
Murray Herbert Gibson Munro
Sylvia Urban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of AU2002217266A1 publication Critical patent/AU2002217266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002217266A 2000-12-13 2001-12-13 Antitumoral carbazoles Abandoned AU2002217266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0030417 2000-12-13
GBGB0030417.0A GB0030417D0 (en) 2000-12-13 2000-12-13 An anticancer lead compound isolated from a New Zealand ascidian
PCT/GB2001/005523 WO2002048107A1 (en) 2000-12-13 2001-12-13 Antitumoral carbazoles

Publications (1)

Publication Number Publication Date
AU2002217266A1 true AU2002217266A1 (en) 2002-06-24

Family

ID=9905016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217266A Abandoned AU2002217266A1 (en) 2000-12-13 2001-12-13 Antitumoral carbazoles

Country Status (11)

Country Link
US (1) US7135494B2 (ja)
EP (1) EP1349837A1 (ja)
JP (1) JP2004518650A (ja)
AU (1) AU2002217266A1 (ja)
BR (1) BR0116123A (ja)
CA (1) CA2431107A1 (ja)
GB (1) GB0030417D0 (ja)
IL (1) IL156372A0 (ja)
MX (1) MXPA03005374A (ja)
NZ (1) NZ526399A (ja)
WO (1) WO2002048107A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530496B2 (en) 2008-07-08 2013-09-10 Trustees Of Dartmouth College Compositions and methods for treating cancer
US8765781B2 (en) 2008-07-08 2014-07-01 Trustees Of Dartmouth College Bis-carbazole DNA intercalating agents for antitumor therapy
US8975274B2 (en) 2011-09-20 2015-03-10 Trustees Of Dartmouth College Compositions and methods for treating cancer
HUE040055T2 (hu) 2012-09-25 2019-02-28 Chugai Pharmaceutical Co Ltd RET inhibitor
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI825163B (zh) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法
WO2023220558A1 (en) * 2022-05-09 2023-11-16 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination of curaxins and immune checkpoint inhibitors for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0331257A (ja) 1989-06-28 1991-02-12 Kissei Pharmaceut Co Ltd インドール誘導体の製造方法
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH08157475A (ja) 1994-11-29 1996-06-18 Kissei Pharmaceut Co Ltd １−ヒドロキシインドール誘導体

Also Published As

Publication number Publication date
MXPA03005374A (es) 2004-03-26
WO2002048107A1 (en) 2002-06-20
BR0116123A (pt) 2003-10-14
US20040072890A1 (en) 2004-04-15
EP1349837A1 (en) 2003-10-08
IL156372A0 (en) 2004-01-04
US7135494B2 (en) 2006-11-14
CA2431107A1 (en) 2002-06-20
GB0030417D0 (en) 2001-01-24
JP2004518650A (ja) 2004-06-24
NZ526399A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
TW442490B (en) Tricyclic erythromycin derivatives
US7135494B2 (en) Antitumoral carbazoles
WO2019238046A1 (zh) 喜树碱衍生物及其制备方法和应用
JPH11507636A (ja) 新規なクリプトフィシン
EP1399411B1 (en) Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies
CN109796468B (zh) 大环nannocystin衍生物、及其制备方法和用途
JP2012514041A (ja) （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法
WO2018086242A1 (zh) pH敏感的轴向取代硅酞菁配合物及其制备方法和在医药上的应用
CN113387932B (zh) 一种诱导brd4蛋白降解的双功能化合物
AU2002258050A1 (en) Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies
JP3776799B2 (ja) 五環性タキサン化合物
US20230227493A1 (en) Carboxy substituted glucocorticoid receptor agonists
US6403636B1 (en) Xanthone compounds, their preparation and use as medicament
BRPI0617730A2 (pt) agente para prevenir ou tratar cáncer do páncreas, cáncer de ovário ou cáncer hepático contendo nova pró-fármaco hidrossolúvel
US6677456B2 (en) Pentacyclic taxan compound
CN113024557B (zh) 一种Peganumine A生物碱结构简化物及其应用
AU2001233873B2 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CS195343B2 (en) Method of producing derivatives of dimere indol-dihydro-indoldiones
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20100256177A1 (en) Flavopereirine derivatives for cancer therapy
KR101567940B1 (ko) 신규한 광학 활성 (테트라히드로퀴놀린-4-일)말로네이트 유도체 및 이의 항암효과
US20240101585A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
JP2004010565A (ja) 光線力学的療法剤、抗癌剤、新規なキノキサリン誘導体および医薬組成物
JPH0834789A (ja) ピロロインドールカルボン酸エステル誘導体及びその製造方法
TW201825510A (zh) 細胞穿透肽序列

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application